John Libbey Eurotext

European Journal of Dermatology


A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair ®), in the treatment of mild to moderate atopic dermatitis Volume 15, numéro 1, January-February 2005

European Institute of Dermatology, Viale Puglie 15, 20137 Milan, Italy, Institute of Dermatological Sciences, I.R.C.C.S., University of Milan, Via Pace 9, 20122 Milan, Italy Fax: (0039) 50 32 07 79.

MAS063D (Atopiclair ®) is a hydrolipidic cream that has been developed for the management of atopic dermatitis (AD). The putative active ingredients of MAS063D are hyaluronic acid, telmesteine, Vitis vinifera, glycyrrhetinic acid. A five-week study in 30 adult patients with mild to moderate AD showed that MAS063D offered significant benefits over a vehicle-only control. MAS063D improved the total body area affected (17.2% → 13.2%, p < 0.001), itch score (2.7 → 1.3 on a 10-point scale, p = 0.001) and EASI score (28.3 → 24.3, p = 0.024) after 22 days treatment compared to baseline. The patients’ opinion of MAS063D (patient’s view of itch control, and view of study substance) was rated by participating patients as significantly better than control (p = 0.008, p = 0.042 respectively). Based on these preliminary results in a small scale study, it is suggested that MAS063D is a possible new treatment option for improving signs and symptoms in adults with mild to moderate AD.